Free tool
FAERS Monitor: Transderm Scop
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 017874 or its brand name (Transderm Scop, Scopolamine). Reports on generic versions are filed under their own applications.
Reports
5,759
Serious
3,941
68% of reports
Hospitalization
1,951
Death reported
765
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- nausea711
- off label use609
- vomiting501
- dizziness454
- headache366
- drug ineffective346
- fatigue300
- vision blurred279
- death257
- diarrhoea252
- malaise252
- confusional state243
- pain241
- dyspnoea207
- dry mouth205
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 32 |
| 2005 | 48 |
| 2006 | 60 |
| 2007 | 51 |
| 2008 | 92 |
| 2009 | 85 |
| 2010 | 118 |
| 2011 | 262 |
| 2012 | 248 |
| 2013 | 135 |
| 2014 | 143 |
| 2015 | 169 |
| 2016 | 539 |
| 2017 | 408 |
| 2018 | 370 |
| 2019 | 356 |
| 2020 | 221 |
| 2021 | 309 |
| 2022 | 510 |
| 2023 | 483 |
| 2024 | 403 |
| 2025 | 394 |
| 2026 | 322 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,048,400 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| dry mouthSignal | 205 | 9.2 | 8.1 | 1,502 |
| vision blurredSignal | 279 | 7.4 | 6.6 | 1,554 |
| confusional stateSignal | 243 | 5.5 | 4.9 | 895 |
| vomitingSignal | 501 | 3.9 | 3.6 | 1,098 |
| dizzinessSignal | 454 | 3.3 | 3.0 | 754 |
| nauseaSignal | 711 | 3.3 | 3.1 | 1,169 |
| off label useSignal | 609 | 2.5 | 2.4 | 592 |
| headacheSignal | 366 | 2.1 | 1.9 | 226 |
| malaiseSignal | 252 | 2.1 | 1.9 | 147 |
| pain | 241 | 1.4 | 1.3 | 32 |
| diarrhoea | 252 | 1.4 | 1.3 | 33 |
| fatigue | 300 | 1.4 | 1.3 | 36 |
| dyspnoea | 207 | 1.3 | 1.2 | 18 |
| death | 257 | 1.1 | 1.0 | 2 |
| drug ineffective | 346 | 1.0 | 0.9 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.